Citius Pharmaceuticals (CTXR) Q2 2025 Earnings Report

Citius Pharmaceuticals reported QQ2 2025 results with no revenue disclosed for the quarter, continuing a pre-revenue profile typical of early-stage biotech. Net income came in at -$11.51 million for the quarter, translating to an EPS of -$0.0662. YoY, net income declined by 34.7% and EPS by 23.3%, while QoQ declines were ~17.9% for net income and ~17.8% for EPS, underscoring sustained operating losses during ongoing development activities. R&D expenses totaled $3.77 million, with G&A of $4.79 million and other expenses of $2.70 million, contributing to total operating expenses of $11.26 million. The company does not report revenue in the quarter, signaling continued dependency on external financing to support its pipeline and corporate operations.

From a balance-sheet perspective, CTXR carried total assets of approximately $121.48 million against total liabilities of $57.91 million, yielding a stockholders’ equity position of about $60.66 million. Notably, intangible assets stand at roughly $92.80 million with goodwill of about $9.35 million, and accumulated deficit remains substantial at approximately -$222.05 million, reflecting a long history of R&D investment and operating losses. Cash and cash equivalents were reported at $26.41 million, with liquidity metrics showing a current ratio of 0.37, a quick ratio of 0.061, and a cash ratio near 0.0005—indicating meaningful liquidity challenges in meeting near-term obligations without financing. Net debt stood at about $0.91 million, suggesting modest debt load relative to assets, but cash runway remains tight given ongoing cash burn.

Overall, the QQ2 2025 results emphasize a high-risk, high-potential profile: substantial IP and a diversified pipeline (MinoLok, MinoWrap, HaloLido, NoveCite, IONTAK) offer meaningful long-term upside if regulatory milestones are achieved, but the current lack of revenue, persistent losses, and liquidity constraints necessitate continued equity or debt financing and disciplined capital management. Investors should monitor milestone progress, potential strategic collaborations, and any management commentary on runway and monetization opportunities as catalysts for a value realization path.